Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive ControlNiresh Hariparsad, Donald Tweedie, Joshua G. DeKeyser et al.|Drug Metabolism and Disposition|2017Cited by 46
Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry PerspectiveOdette A. Fahmi, Mohamad Shebley, Jairam Palamanda et al.|Drug Metabolism and Disposition|2016Cited by 45
Evaluation of CYP1A1 and CYP2B1/2 m-RNA Induction in Rat Liver Slices Using the NanoString® Technology: A Novel Tool for Drug Discovery Lead OptimizationJairam Palamanda, Amin A. Nomeir, Pramila Kumari et al.|Drug Metabolism Letters|2009Cited by 5
Considerations from the IQ induction working group in response to drug–drug interaction guidances from regulatory agenciesNiresh Hariparsad, Donald Tweedie, Heidi J. Einolf et al.|Drug Metabolism and Pharmacokinetics|2018Cited by 0